{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:17:45Z","timestamp":1791231465958,"version":"4.1.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The tyrosine kinase inhibitor imatinib is highly effective in the treatment of chronic myelogenous leukemia (CML), but primary and acquired resistance of CML cells to the drug offset its efficacy. Molecular mechanisms for resistance of CML to tyrosine kinase inhibitors are not fully understood. In the present study, we show that BCR-ABL activates the expression of the mammalian stress response gene SIRT1 in hematopoietic progenitor cells and that this involves STAT5 signaling. SIRT1 activation promotes CML cell survival and proliferation associated with deacetylation of multiple SIRT1 substrates, including FOXO1, p53, and Ku70. Imatinib-mediated inhibition of BCR-ABL kinase activity partially reduces SIRT1 expression and SIRT1 inhibition further sensitizes CML cells to imatinib-induced apoptosis. Knockout of SIRT1 suppresses BCR-ABL transformation of mouse BM cells and the development of a CML-like myeloproliferative disease, and treatment of mice with the SIRT1 inhibitor tenovin-6 deters disease progression. The combination of SIRT1 gene knockout and imatinib treatment further extends the survival of CML mice. Our results suggest that SIRT1 is a novel survival pathway activated by BCR-ABL expression in hematopoietic progenitor cells, which promotes oncogenic transformation and leukemogenesis. Our findings suggest further exploration of SIRT1 as a therapeutic target for CML treatment to overcome resistance.<\/jats:p>","DOI":"10.1182\/blood-2011-06-361691","type":"journal-article","created":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T23:19:40Z","timestamp":1325200780000},"page":"1904-1914","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":165,"title":["Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis"],"prefix":"10.1182","volume":"119","author":[{"given":"Hongfeng","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Cancer Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematopoietic Stem Cell and Leukemia Research, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Modi","sequence":"additional","affiliation":[{"name":"Division of Hematopoietic Stem Cell and Leukemia Research, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horne","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Division of Hematopoietic Stem Cell and Leukemia Research, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenYong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111811043339200_B1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2019111811043339200_B2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib.","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2019111811043339200_B3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2019111811043339200_B4","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111811043339200_B5","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111811043339200_B6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111811043339200_B7","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606.","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111811043339200_B8","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"2019111811043339200_B9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1101\/sqb.2007.72.024","article-title":"Sirtuins in aging and disease.","volume":"72","author":"Guarente","year":"2007","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"2","key":"2019111811043339200_B10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-8674(01)00524-4","article-title":"Negative control of p53 by Sir2alpha promotes cell survival under stress.","volume":"107","author":"Luo","year":"2001","journal-title":"Cell"},{"issue":"2","key":"2019111811043339200_B11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0092-8674(01)00527-X","article-title":"hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.","volume":"107","author":"Vaziri","year":"2001","journal-title":"Cell"},{"issue":"5682","key":"2019111811043339200_B12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1126\/science.1099196","article-title":"Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.","volume":"305","author":"Cohen","year":"2004","journal-title":"Science"},{"issue":"4","key":"2019111811043339200_B13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0092-8674(04)00126-6","article-title":"Mammalian SIRT1 represses forkhead transcription factors.","volume":"116","author":"Motta","year":"2004","journal-title":"Cell"},{"issue":"5666","key":"2019111811043339200_B14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.1094637","article-title":"Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.","volume":"303","author":"Brunet","year":"2004","journal-title":"Science"},{"issue":"27","key":"2019111811043339200_B15","doi-asserted-by":"crossref","first-page":"10042","DOI":"10.1073\/pnas.0400593101","article-title":"Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity.","volume":"101","author":"Daitoku","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2019111811043339200_B16","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1158\/0008-5472.CAN-07-0085","article-title":"SIRT1 Ii significantly elevated in mouse and human prostate cancer.","volume":"67","author":"Huffman","year":"2007","journal-title":"Cancer Res"},{"issue":"10","key":"2019111811043339200_B17","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"2019111811043339200_B18","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/PAS.0b013e31816b6478","article-title":"SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.","volume":"32","author":"Jang","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2019111811043339200_B19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/modpathol.2009.49","article-title":"SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.","volume":"22","author":"Nosho","year":"2009","journal-title":"Mod Pathol"},{"issue":"5","key":"2019111811043339200_B20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cell.2008.10.025","article-title":"SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging.","volume":"135","author":"Oberdoerffer","year":"2008","journal-title":"Cell"},{"issue":"4","key":"2019111811043339200_B21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ccr.2008.09.001","article-title":"Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.","volume":"14","author":"Wang","year":"2008","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111811043339200_B22","first-page":"1678","article-title":"HIC1 hypermethylation is a late event in hematopoietic neoplasms.","volume":"57","author":"Issa","year":"1997","journal-title":"Cancer Res"},{"issue":"3","key":"2019111811043339200_B23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2005.08.011","article-title":"Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.","volume":"123","author":"Chen","year":"2005","journal-title":"Cell"},{"issue":"8","key":"2019111811043339200_B24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/onc.2010.468","article-title":"NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.","volume":"30","author":"Wang","year":"2011","journal-title":"Oncogene"},{"issue":"15","key":"2019111811043339200_B25","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/0008-5472.CAN-03-3656","article-title":"Effect of mutational inactivation of tyrosine kinase activity on BCR\/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.","volume":"64","author":"Ramaraj","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"2019111811043339200_B26","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","article-title":"BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.","volume":"285","author":"Yuan","year":"2010","journal-title":"J Biol Chem"},{"issue":"5704","key":"2019111811043339200_B27","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1126\/science.1101731","article-title":"Nutrient availability regulates SIRT1 through a forkhead-dependent pathway.","volume":"306","author":"Nemoto","year":"2004","journal-title":"Science"},{"issue":"19","key":"2019111811043339200_B28","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1073\/pnas.1934713100","article-title":"Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice.","volume":"100","author":"Cheng","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111811043339200_B29","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow.","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2019111811043339200_B30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccr.2008.03.004","article-title":"Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.","volume":"13","author":"Lain","year":"2008","journal-title":"Cancer Cell"},{"issue":"7","key":"2019111811043339200_B31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","article-title":"SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells.","volume":"121","author":"Kiel","year":"2005","journal-title":"Cell"},{"key":"2019111811043339200_B32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-59745-182-6_5","article-title":"Flow cytometry-based cell cycle measurement of mouse hematopoietic stem and progenitor cells.","volume":"Vol 430","author":"Shen","year":"2008","journal-title":"Hematopoietic stem cell protocols"},{"issue":"19","key":"2019111811043339200_B33","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.4161\/cc.7.19.6799","article-title":"JNK2-dependent regulation of SIRT1 protein stability.","volume":"7","author":"Ford","year":"2008","journal-title":"Cell Cycle"},{"issue":"4","key":"2019111811043339200_B34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.molcel.2007.01.011","article-title":"Phosphorylation of HuR by Chk2 regulates SIRT1 expression.","volume":"25","author":"Abdelmohsen","year":"2007","journal-title":"Mol Cell"},{"issue":"2","key":"2019111811043339200_B35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1083\/jcb.200809167","article-title":"A c-Myc-SIRT1 feedback loop regulates cell growth and transformation.","volume":"185","author":"Yuan","year":"2009","journal-title":"J Cell Biol"},{"issue":"9","key":"2019111811043339200_B36","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ncb1468","article-title":"Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.","volume":"8","author":"Wang","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"47","key":"2019111811043339200_B37","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1038\/sj.onc.1210758","article-title":"Aberrant cytokine signaling in leukemia.","volume":"26","author":"Van Etten","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"2019111811043339200_B38","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V96.6.2269","article-title":"Bcr\/Abl activates transcription of the Bcl-X gene through STAT5.","volume":"96","author":"Gesbert","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2019111811043339200_B39","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1097-2765(01)00357-4","article-title":"BCR\/ABL regulates mammalian RecA homologs, resulting in drug resistance.","volume":"8","author":"Slupianek","year":"2001","journal-title":"Mol Cell"},{"issue":"3","key":"2019111811043339200_B40","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1091\/mbc.e07-09-0965","article-title":"SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity.","volume":"19","author":"Narala","year":"2008","journal-title":"Mol Biol Cell"},{"issue":"11","key":"2019111811043339200_B41","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.V82.11.3327.3327","article-title":"Mouse strain variability in the expression of the hematopoietic stem cell antigen Ly-6A\/E by bone marrow cells.","volume":"82","author":"Spangrude","year":"1993","journal-title":"Blood"},{"issue":"6","key":"2019111811043339200_B42","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1101\/gad.1643908","article-title":"Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.","volume":"22","author":"Hennighausen","year":"2008","journal-title":"Genes Dev"},{"issue":"11","key":"2019111811043339200_B43","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/blood.V99.11.4122","article-title":"BCR-ABL-induced adhesion defects are tyrosine kinase-independent.","volume":"99","author":"Wertheim","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111811043339200_B44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/carcin\/23.5.817","article-title":"Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice.","volume":"23","author":"Berrigan","year":"2002","journal-title":"Carcinogenesis"},{"issue":"4","key":"2019111811043339200_B45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2004.08.030","article-title":"Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.","volume":"6","author":"Chen","year":"2004","journal-title":"Cancer Cell"},{"issue":"16","key":"2019111811043339200_B46","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1093\/emboj\/17.16.4657","article-title":"Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.","volume":"17","author":"Venkatachalam","year":"1998","journal-title":"EMBO J"},{"issue":"3","key":"2019111811043339200_B47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng1193-225","article-title":"Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.","volume":"5","author":"Harvey","year":"1993","journal-title":"Nat Genet"},{"issue":"3","key":"2019111811043339200_B48","doi-asserted-by":"crossref","first-page":"e1759","DOI":"10.1371\/journal.pone.0001759","article-title":"SirT1 regulates energy metabolism and response to caloric restriction in mice.","volume":"3","author":"Boily","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"2019111811043339200_B49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cmet.2008.05.004","article-title":"SirT1 inhibition reduces IGF-I\/IRS-2\/Ras\/ERK1\/2 signaling and protects neurons.","volume":"8","author":"Li","year":"2008","journal-title":"Cell Metab"},{"issue":"32","key":"2019111811043339200_B50","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1038\/onc.2009.147","article-title":"SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol.","volume":"28","author":"Boily","year":"2009","journal-title":"Oncogene"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/8\/1904\/1354945\/zh800812001904.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/8\/1904\/1354945\/zh800812001904.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T11:23:49Z","timestamp":1574076229000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/8\/1904\/30394\/Activation-of-stress-response-gene-SIRT1-by-BCRABL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,2,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-361691","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]}}}